Your browser doesn't support javascript.
loading
Partially covered versus uncovered pyloro-duodenal stents for unresectable malignant gastric outlet obstruction: Randomized controlled study.
Teoh, Anthony Yuen Bun; Lakhtakia, Sundeep; Tan, Damien Meng Yew; Crinò, Stefano Francesco; Dhir, Vinay; Kunda, Rastislav; Ang, Tiing Leong; Ho, Khek Yu; Aerts, Maridi; Memon, Sana Fathima; Chan, Shannon Melissa; Chiu, Philip Wai Yan; Conti Bellocchi, Maria Cristina; Messaoudi, Nouredin; Ng, Stephen Ka Kei; Yip, Hon Chi; Gabbrielli, Armando; Khor, Christopher Jen Lock; Ramchandani, Mohan; Ng, Enders Kwok Wai.
  • Teoh AYB; Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Lakhtakia S; Department of Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India.
  • Tan DMY; Department of Gastroenterology and Hepatology, Singapore General Hospital and Duke-NUS Medical School, Singapore City, Singapore.
  • Crinò SF; Gastroenterology and Digestive Endoscopy Unit, Pancreas Institute, University Hospital of Verona, Verona, Italy.
  • Dhir V; Institute of Digestive and Liver Care, SL Raheja Hospital, Mumbai, India.
  • Kunda R; Department of Surgical Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
  • Ang TL; Department of Surgery, Hepatopancreatobiliary Center, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
  • Ho KY; Department of Gastroenterology-Hepatology, Hepatopancreatobiliary Center, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
  • Aerts M; Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore City, Singapore.
  • Memon SF; Department of Medicine, National University of Singapore, Singapore City, Singapore.
  • Chan SM; Department of Gastroenterology-Hepatology, Hepatopancreatobiliary Center, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
  • Chiu PWY; Department of Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India.
  • Conti Bellocchi MC; Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Messaoudi N; Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Ng SKK; Gastroenterology and Digestive Endoscopy Unit, Pancreas Institute, University Hospital of Verona, Verona, Italy.
  • Yip HC; Department of Surgery, Hepatopancreatobiliary Center, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
  • Gabbrielli A; Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Khor CJL; Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Ramchandani M; Gastroenterology and Digestive Endoscopy Unit, Pancreas Institute, University Hospital of Verona, Verona, Italy.
  • Ng EKW; Department of Gastroenterology and Hepatology, Singapore General Hospital and Duke-NUS Medical School, Singapore City, Singapore.
Dig Endosc ; 36(4): 428-436, 2024 Apr.
Article en En | MEDLINE | ID: mdl-37522554
ABSTRACT

OBJECTIVES:

The aim of the current study was to compare the efficacy of partially covered duodenal stent (PCDS) vs. uncovered duodenal stent (UCDS) in patients suffering from unresectable primary malignant gastric outlet obstruction (GOO).

METHODS:

This was a prospective international randomized controlled study conducted in 10 high-volume institutions. Consecutive patients suffering from malignant GOO were recruited. The primary outcome measurement was the reintervention rate. Secondary outcomes included technical and clinical success, 30-day adverse events, 30-day mortality, causes of stent dysfunction, and the duration of stent patency.

RESULTS:

Between March 2017 and October 2020, 115 patients (59 PCDS, 56 UCDS) were recruited. The 1-year reintervention was not significantly different (PCDS vs. UDCS = 12/59, 20.3% vs. 14/56, 25%, P = 0.84). There was a trend to fewer patients with tumor ingrowth in the PCDS group (6/59 [10.2%]) vs. 13/56 [23.2%], P = 0.07). There were no significant differences in the technical success (100% vs. 100%, P = 1), clinical success (91.5% vs. 98.2%, P = 0.21), procedural time (21.5 [interquartile range [IQR] 17-30] vs. 20.0 [IQR 15-34.75], P = 0.62), hospital stay (4 [IQR 3-12] vs. 5 [IQR 3-8] days, P = 0.81), 30-day adverse events (18.6% vs. 14.3%, P = 0.62), or 30-day mortality (6.8% vs. 5.2%, P = 1.00).

CONCLUSION:

The use of PCDS was associated with a lower risk of tumor ingrowth but did not improve on reintervention rates or stent patency. Both kinds of stents could be used in this group of patients.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Obstrucción de la Salida Gástrica / Neoplasias Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Obstrucción de la Salida Gástrica / Neoplasias Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article